Fosamax and Osteonecrosis of the Jaw: Clinical Evidence Review

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

Legacy of General Health and Science Information

The legacy of general health and science information dissemination has long served as a foundation for public awareness, emphasizing broad educational outreach and preventive care. Within this heritage, the focus on bone health and medication safety has been a recurring theme, particularly in discussions surrounding osteoporosis management. Over time, this general context has evolved to accommodate more specific inquiries, such as the clinical review of Fosamax and its potential association with osteonecrosis of the jaw. This shift reflects a natural progression from population-level health guidance to targeted pharmacovigilance, where the risks and benefits of therapeutic agents are scrutinized in detail. As the discourse matures, attention increasingly turns to occupational exposure scenarios, where individuals may encounter similar risk factors in professional settings. The transition from a general health framework to an occupational concern involves recognizing that certain populations, such as healthcare workers or those involved in pharmaceutical manufacturing, might face unique exposure patterns. This pivot does not delve into mechanistic claims but rather acknowledges the need for systematic observation of real-world conditions. By bridging the gap between clinical evidence review and workplace safety, the focus now centers on how occupational environments can influence health outcomes, thereby extending the legacy of informed inquiry into new domains of practical relevance.

Clinical Evidence and Pharmacological Background

Fosamax (alendronate sodium) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its clinical utility in reducing fracture risk is well established, but the drug is also associated with a serious adverse effect: osteonecrosis of the jaw (ONJ). ONJ is a condition characterized by exposed, non-healing bone in the maxillofacial region, often presenting with pain, swelling, infection, and delayed healing after dental procedures. Clinical presentation can vary, but the hallmark is necrotic bone that persists for weeks to months. Diagnosis is typically based on clinical examination and imaging, with exclusion of metastatic disease or other causes. The condition can occur spontaneously, but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Multiscale characterization of jawbone tissue has provided comprehensive information to help understand jawbone-specific responses to bone-related complications, including bisphosphonate-related ONJ (https://pubmed.ncbi.nlm.nih.gov/40345077/).

Mechanistic Pathways and Risk Factors

The mechanistic pathways linking Fosamax to ONJ involve the drug's pharmacology as a bisphosphonate. Bisphosphonates inhibit osteoclast-mediated bone resorption, which reduces bone turnover. In the jaw, which has high remodeling rates, this suppression can impair the normal repair of microdamage and compromise blood supply, leading to avascular necrosis. Additionally, bisphosphonates may have anti-angiogenic effects and can accumulate in bone tissue over years of use. The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Adequacy of Warnings and Causation Considerations

Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific section on ONJ under "Warnings and Precautions." It states that ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The label also notes that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the label does not provide specific guidance on the optimal duration of use for fracture prevention, noting that the optimal duration has not been determined and that for low-risk patients, drug discontinuation after 3 to 5 years may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This lack of definitive duration guidance may affect risk communication. Causation-related considerations for affected patients are complex. The time to onset of symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping, but a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This suggests that while ONJ is a known adverse effect, its incidence in clinical trials may be low, and other factors (e.g., dental procedures, comorbidities) often contribute. The timeline between exposure and documented harm can range from months to years, with risk increasing with longer bisphosphonate use. For patients who develop ONJ, management typically involves discontinuation of the bisphosphonate, conservative debridement, infection control, and avoidance of further invasive dental procedures.

Summary and Clinical Recommendations

In summary, Fosamax is an effective osteoporosis treatment, but its use carries a risk of ONJ, particularly with prolonged exposure and in the presence of dental risk factors. The prescribing information includes warnings, but the optimal duration of therapy remains uncertain. Patients should be counseled on maintaining good oral hygiene and undergoing dental evaluations before starting bisphosphonate therapy. If ONJ occurs, prompt discontinuation and supportive care are recommended.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Fosamax and what is it used for?

What is osteonecrosis of the jaw (ONJ) and how is it related to Fosamax?

Osteonecrosis of the jaw (ONJ) is a condition characterized by exposed, non-healing bone in the maxillofacial region, often presenting with pain, swelling, infection, and delayed healing after dental procedures. Fosamax is associated with ONJ as a serious adverse effect, particularly with prolonged use and in the presence of dental risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What are the risk factors for developing ONJ while taking Fosamax?

Known risk factors include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Check Whether Your Situation Qualifies

Free and confidential. No obligation — an initial records screening only.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.